top of page



Founder, President, & CEO

Michael Whitman is the founder and CEO of Micro Interventional Devices, Inc. (MID). Michael has over 35 years of medical device experience at market leading firms including, Johnson and Johnson, Olympus, Synthes and Power Medical Interventions. He previously was the founder and CEO of Power Medical Interventions (NASDAQ; PMII), which was acquired by Covidien Ltd. in 2009. Prior to founding PMI, Michael served in numerous management positions at Johnson and Johnson during his 13-year tenure including Vice President of Sales, Director of Sales and Marketing, Product Development and Product Management. He is the named inventor on over 55 US and foreign patents. He received his A.B. in Business and Economics from Lafayette College and completed graduate work at Wharton, University of Michigan, Harvard Executive Education, and Rutgers University.


Managing Partner, Runway Healthcare; Managing Partner, Lucius Partners

Jeffrey O'Donnell, Sr. has extensive experience in the Healthcare industry, merging a solid, traditional corporate background with emerging growth leadership.  Jeff brings more than 25 years of Board and Chief Executive experience running emerging medical device firms.  Businesses under his direct leadership have achieved over $1.8 Billion in value creation form initial public offering of stock or mergers and acquisitions.  Currently, Jeff is the Managing General partner of Runway Healthcare an early stage Medtech Accelerator.  He is also Managing Partner Lucius Partners.  O'Donnell Sr. retired as CEO and founder of Trice Medical an emerging growth medical device company developing optical needles used by orthopedic surgeons to diagnose soft tissue damage of joints.  In 2008, Jeff started and ran Embrella Cardiovascular, a medical device startup company, which sold in 2011 to Edwards Lifesciences (NYSE: EW).  Prior to Embrella Cardiovascular, Jeff served as President and CEO of PhotoMedex (NASDAQ: PHMD) from 1999 to 2009.  Prior to PhotoMedex, Jeff was the President and CEO of Cardiovascular Dynamics.  His team took CCVD public on NASDAQ in June of 1996 and purchased Radiance Medical Systems and Endologix (NASDAQ: ELGX).  From 1994 to 1995, Jeff held the position of President and CEO of Kensey Nash Corporation (NASDAQ: KNSY).  Additionally, he has held several senior sales and marketing management positions at Boston Scientific Corporation, Guidant Corporation and with Johnson & Johnson Orthopedic Division.  In 2005, Jeff was named LifeSciences CEO of the Year by Price Waterhouse Coopers. 


Gerald Dorros, MD, ScD, FACC, FESC, FACP, FSVMB, FAHA (emeritus), FCCP, FACA, Medical Director of the Dorros Fueur Interventional Cardiovascular Disease Foundations Ltd

Gerald Dorros, M.D. was the third individual to perform angioplasty in the US in 1978. He initiated the use of angioplasty as a primary therapy for peripheral vascular disease in 1979, and is a world-renowned cardiovascular interventionalist. He is the Medical Director of the Dorros Feuer Interventional Cardiovascular Disease Foundation Ltd. Dr. Dorros previously served as President of the Arizona Heart Institute Foundation and previously was a partner of the Milwaukee Heart and Vascular Clinic. He has made numerous contributions to the management of heart and peripheral vascular disease, renovascular hypertension and critical limb ischemia, including pioneering work in stent supported renal angioplasty, carotid stent supported angioplasty, and endovascular repair of thoracic and abdominal aortic aneurysm in high-risk surgical patients. Dr. Dorros has an exceptional understanding of how less invasive procedures, enabled by new technologies, can benefit patients.


Managing Partner, Originate Ventures, LLC

Mike Gausling is a co-founder and Managing Partner of Originate Ventures LLC, a venture capital investment firm which targets early stage and emerging growth product companies in Eastern Pennsylvania. Prior to Originate Ventures, Mike was a co-founder and former CEO of OraSure Technologies (NASDAQ: OSUR), where he helped build the company from a start-up to more than $50 million in annual sales and a market cap of over $500 million.Mike is the Treasurer of Lehigh Valley Industrial Park (LVIP), a local non-profit land development company and a Board member for the Community Action Committee of the Lehigh Valley. Mike earned a BS in Mechanical Engineering from Rensselaer Polytechnic Institute and received an MBA in Finance from Miami University of Ohio.


Former Chief Executive Officer and President, Neuronetics, Inc.

Christopher A. Thatcher is the former President and Chief Executive Officer at Neuronetics, Inc.  He has over 20 years of experience specializing in the development and successful commercialization of new medical device products.  Currently at Neuronetics, Mr. Thatcher is the driving force for this pioneer and innovator in Transcranial Magnetic Stimulation therapy for Major Depressive Disorder.  His focus is on continuing to accelerate its position as a global market leader in TMS with the NeuroStar TMS Therapy System.  Mr. Thatcher has previously held executive positions at Reichert Technologies, a unit of AMETEK Ultra Precision Technologies, Integra Lifesciences, Bausch and Lomb, and Allergan.  His strengths in optimizing product development, strategic decision-making, and streamlining operations will be of great value to MID.

bottom of page